Emerging Tx for Adv EC

CE / CME

Emerging Therapies for Advanced Endometrial Cancer

ABIM MOC: maximum of 1.00 Medical Knowledge MOC point

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: September 18, 2023

Expiration: September 17, 2024

Hye Sook Chon
Hye Sook Chon, MD
Ritu Salani
Ritu Salani, MD, MBA

Activity

Progress
1
Course Completed

Introduction

In this module, Hye Sook Chon, MD, discusses emerging data and ongoing clinical trials of promising investigational strategies for the treatment of advanced or recurrent endometrial cancer. These strategies range from systemic therapy with immunotherapy-based combination regimens, selinexor, and trastuzumab deruxtecan to therapy de-escalation.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slideset that can be found here or downloaded by clicking any of the slide thumbnails in the module alongside the expert commentary.

Clinical Care Options plans to measure the educational impact of this activity. A few questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

Poll

For those providing patient care, how many patients with endometrial cancer do you provide care for in a typical month?

In your current practice, how confident are you in communicating with patients the therapeutic and prognostic implications of evidence-based molecular profiling and the associated benefits of clinical trial enrollment considering the molecular profile of their disease?
Please rate your confidence on a scale of 1 to 7.